Lundbeck drug shows significantly improved functioning in major depressive disorder
According to Lundbeck, new trial results demonstrate that the firm's antidepressant Brintellix significantly improves overall functioning in people suffering from severe depression.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
On Thursday morning, Lundbeck reported receiving positive data for the company's antidepressant Brintellix (generic name vortioxetin). In the firm's Relieve study, the drug has shown promise in improving severely depressed patients' ability to function.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck carries on Rexulti study after new analysis
For subscribers
Lundbeck drug hope moves closer to moment of truth
For subscribers
